Prophylactic Effect of Probiotics on the Development of Experimental Autoimmune Myasthenia Gravis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Chae, Chang Suk ^a   Kwon, Ho Keun ^a,b   Hwang, Ji Sun ^a   Kim, Jung Eun ^a   Im, Sin Hyeog ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 6; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BIFIDOBACTERIUM BIFIDUM; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; FEMALE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS REUTERI; LYMPHOCYTE PROLIFERATION; MYASTHENIA GRAVIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY T LYMPHOCYTE; STREPTOCOCCUS THERMOPHILUS; T LYMPHOCYTE; TREATMENT RESPONSE; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES; AUTOANTIBODIES; CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; IMMUNE TOLERANCE; INFLAMMATION MEDIATORS; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MESENTERY; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PROBIOTICS; RATS; RECEPTORS, CHOLINERGIC;

MUS;

EID: 84871457480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052119     Document Type: Article

References (62)

1. Itoh T, Fujimoto Y, Kawai Y, Toba T, Saito T, (1995) Inhibition of food-borne pathogenic bacteria by bacteriocins from Lactobacillus gasseri. Lett Appl Microbiol 21: 137-141.
2. Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N, (1995) Immune system stimulation by probiotics. J Dairy Sci 78: 1597-1606.
3. So JS, Kwon HK, Lee CG, Yi HJ, Park JA, et al. (2008) Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol 45: 2690-2699.
4. Isolauri E, Kirjavainen PV, Salminen S, (2002) Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 50Suppl 3: III54-59.
5. Viljanen M, Pohjavuori E, Haahtela T, Korpela R, Kuitunen M, et al. (2005) Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 115: 1254-1259.
6. Kim N, Kunisawa J, Kweon MN, Eog Ji G, Kiyono H, (2007) Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clin Immunol 123: 30-39.
7. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, et al. (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357: 1076-1079.
8. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S, (2000) Probiotics in the management of atopic eczema. Clin Exp Allergy 30: 1604-1610.
9. Bowman LM, Holt PG, (2001) Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. Infect Immun 69: 3719-3727.
10. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, et al. (2005) Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 115: 1260-1267.
11. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108-114.
12. Kuhbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, et al. (2006) Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55: 833-841.
13. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, et al. (2010) Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A 107: 2159-2164.
14. Toyka KV, Brachman DB, Pestronk A, Kao I, (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190: 397-399.
15. Pinching AJ, Peters DK, (1976) Remission of myasthenia gravis following plasma-exchange. Lancet 2: 1373-1376.
16. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG, (1978) Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28: 266-272.
17. Pachner AR, (1987) Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment. Yale J Biol Med 60: 169-177.
18. Conti-Fine BM, Milani M, Kaminski HJ, (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843-2854.
19. Hohlfeld R, Toyka KV, Heininger K, Grosse-Wilde H, Kalies I, (1984) Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 310: 244-246.
20. Sahashi K, Engel AG, Lambert EH, Howard FM Jr, (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39: 160-172.
21. Lennon VA, Seybold ME, Lindstrom JM, Cochrane C, Ulevitch R, (1978) Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 147: 973-983.
22. Karachunski PI, Ostlie NS, Monfardini C, Conti-Fine BM, (2000) Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J Immunol 164: 5236-5244.
23. Im SH, Barchan D, Maiti PK, Raveh L, Souroujon MC, et al. (2001) Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J 15: 2140-2148.
24. Goluszko E, Deng C, Poussin MA, Christadoss P, (2002) Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 122: 85-93.
25. Wang HB, Li H, Shi FD, Chambers BJ, Link H, et al. (2000) Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int Immunol 12: 1381-1388.
26. Ostlie N, Milani M, Wang W, Okita D, Conti-Fine BM, (2003) Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J Immunol 170: 604-612.
27. Balasa B, Deng C, Lee J, Christadoss P, Sarvetnick N, (1998) The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 161: 2856-2862.
28. Gomez CM, Richman DP, (1983) Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A 80: 4089-4093.
29. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ, (1978) Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 298: 1116-1122.
30. Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S, (2004) Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol 152: 112-120.
31. Mahnke K, Johnson TS, Ring S, Enk AH, (2007) Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 46: 159-167.
32. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, et al. (1999) Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 65: 351-354.
33. Akalin AS, Gonc S, Duzel S, (1997) Influence of yogurt and acidophilus yogurt on serum cholesterol levels in mice. J Dairy Sci 80: 2721-2725.
34. de Roos NM, Katan MB, (2000) Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 71: 405-411.
35. Reddy BS, (1999) Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth. J Nutr 129: 1478S-1482S.
36. Parvez S, Malik KA, Ah Kang S, Kim HY, (2006) Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 100: 1171-1185.
37. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, et al. (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23: 1567-1574.
38. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309.
39. Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G, (2007) Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 149: 470-479.
40. Kato I, Endo-Tanaka K, Yokokura T, (1998) Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci 63: 635-644.
41. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, et al. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48: 1565-1575.
42. Lavasani S, Dzhambazov B, Nouri M, Fak F, Buske S, et al. (2010) A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One 5: e9009.
43. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, et al. (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371: 651-659.
44. Losen M, Martinez-Martinez P, Phernambucq M, Schuurman J, Parren PW, et al. (2008) Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann N Y Acad Sci 1132: 174-179.
45. Im SH, Barchan D, Fuchs S, Souroujon MC, (1999) Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest 104: 1723-1730.
46. Deng C, Goluszko E, Tuzun E, Yang H, Christadoss P, (2002) Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol 169: 1077-1083.
47. Yi HJ, Chae CS, So JS, Tzartos SJ, Souroujon MC, et al. (2008) Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor. Mol Immunol 46: 192-201.
48. Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MA, et al. (2010) Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43: 353-370.
49. Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, et al. (1997) Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 186: 385-391.
50. Wang W, Milani M, Ostlie N, Okita D, Agarwal RK, et al. (2007) C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 178: 7072-7080.
51. Mu L, Sun B, Kong Q, Wang J, Wang G, et al. (2009) Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 128: e826-836.
52. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, et al. (2001) Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2: 361-367.
53. Shida K, Makino K, Morishita A, Takamizawa K, Hachimura S, et al. (1998) Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures. Int Arch Allergy Immunol 115: 278-287.
54. Pochard P, Gosset P, Grangette C, Andre C, Tonnel AB, et al. (2002) Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. J Allergy Clin Immunol 110: 617-623.
55. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, et al. (2004) Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53: 694-700.
56. Foligne B, Grangette C, Pot B, (2005) Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects. Gut 54: 727-728.
57. Morelli AE, Thomson AW, (2007) Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 7: 610-621.
58. Gomez AM, Vrolix K, Martinez-Martinez P, Molenaar PC, Phernambucq M, et al. (2011) Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 186: 2503-2513.
59. So JS, Lee CG, Kwon HK, Yi HJ, Chae CS, et al. (2008) Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 46: 172-180.
60. So JS, Song MK, Kwon HK, Lee CG, Chae CS, et al. (2011) Lactobacillus casei enhances type II collagen/glucosamine-mediated suppression of inflammatory responses in experimental osteoarthritis. Life Sci 88: 358-366.
61. Gervasio OL, Phillips WD, (2005) Increased ratio of rapsyn to ACh receptor stabilizes postsynaptic receptors at the mouse neuromuscular synapse. J Physiol 562: 673-685.
62. Martinez-Martinez P, Phernambucq M, Steinbusch L, Schaeffer L, Berrih-Aknin S, et al. (2009) Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding. Neurobiol Dis 35: 14-23.